Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Sichuan Baili Pharmaceutical Co. Ltd. is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is distributed across 1 distinct examiner and 1 distinct art unit. Sean E. Aeder is the busiest examiner for the portfolio, handling the 1 pending office action.
The consolidation of pending work under a specific examiner suggests a dedicated point of contact for the company's current patent applications. This structure simplifies the prosecution landscape for the company's biotechnology and pharmaceutical intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16760466 | BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | AEDER, SEAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16760466 | BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | AEDER, SEAN E | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16760466 | BISPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | AEDER, SEAN E | 1642 | §103§112 | Non-Final OA | — | Pending | Apr 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSichuan Baili Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean E Aeder has the most, with 1 of Sichuan Baili Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
